ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2013

Mar 14, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2013-03-12

Reporting Person: Wyrick Susan D. (PAO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-03-12	Stock Option (right to buy)	$11.95	A	4125	Acquired	2023-03-12	Common Stock (4125)	Direct
2013-03-12	Restricted Stock Unit (RSU)	$	A	2063	Acquired	2017-01-31	Common Stock (2063)	Direct
2013-03-12	Restricted Stock Unit (RSU)	$	A	5000	Acquired	2014-07-31	Common Stock (5000)	Direct

Footnotes

F1: The options vest in monthly installments over 48 months commencing one month from January 1, 2013.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.

F3: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.

F4: Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) achievement of both the successful enrollment and release of data from certain clincial trails, and (ii) the first trading day thereafter on which the issuer's trading window is open, although less than 100% of the total shares may vest upon the achievement of certain, but not all, of the milestones.